Your session is about to expire
← Back to Search
MW150 for Alzheimer's Disease (SKI-AD Trial)
SKI-AD Trial Summary
This trial is testing a new drug for Alzheimer's disease. The goals are to see if it is safe and if it improves cognition, daily living, and behavior.
SKI-AD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSKI-AD Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SKI-AD Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My mental health medications have been the same for the last 2 months.I do not have central nervous system disorders other than Alzheimer's.I am between 50 and 90 years old.I have been diagnosed with Alzheimer's Disease.I have someone who can come with me to appointments and sees me often.I do not have any serious or unstable health conditions.I am a man and agree to use birth control if my partner can get pregnant.I am a woman who cannot become pregnant because I am postmenopausal or have been surgically sterilized.I do not have major brain abnormalities like hydrocephalus or brain tumors.I don't have any health issues that would stop me from joining the study.I have chronic hepatitis B or C.I have an immune disorder treated with immunosuppressants in the last year.I can hear and see well enough for daily activities.I have been diagnosed with HIV.I have had COVID-19 or another viral infection in the last 3 months.
- Group 1: 10mg MW150 daily
- Group 2: placebo daily
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What results are researchers expecting to gain from this experiment?
"This 84-day trial is designed to evaluate the safety of a certain drug, with cognitive changes assessed using the Alzheimer's disease Assessment Scale (ADAScog), MiniMental State Examination (MMSE) and Trails A/B tests."
Are there any openings for participation in this clinical trial?
"Per the clinicaltrials.gov database, this study is not presently in search of participants. Initially posted on May 1st 2022 and last updated a few months ago on March 13th 2022, there are 546 other trials currently taking new members."
What risks are associated with the use of MW150 for patient care?
"Our team at Power has evaluated MW150's safety, assigning it a score of 2 due to the fact that Phase 2 trials have only yielded data pertaining to its safety and not efficacy."
Are individuals of a younger age eligible for this exploration?
"As specified in the trial's eligibility requirements, participants must be between 50 and 90 years old."
Is there a certain demographic that is recommended to be involved in this clinical exploration?
"This clinical research is searching for 24 volunteers aged between 50 and 90 years old who have been diagnosed with Alzheimer's disease. In addition, potential participants must be able to provide informed consent (or through a legally authorized representative), their gender must match the criteria set out by NIAA-AA guidelines, they need to possess fluency in English, at least 8 years of schooling, functioning auditory and visual abilities; an MMSE score ranging from 14 to 28 and a CDR Global Score of 0.5 - 2.0 while having no suicidal thoughts or attempts within the past 12 months."
Share this study with friends
Copy Link
Messenger